Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018’, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS)

The report reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Human Immunodeficiency Virus (HIV) Infections (AIDS) therapeutics and enlists all their major and minor projects

The report assesses Human Immunodeficiency Virus (HIV) Infections (AIDS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

AdAlta Ltd

Advanced Genetic Systems Inc

Aelix Therapeutics SL

Akshaya Bio Inc

Altor BioScience Corp

Altravax Inc

Amarna Therapeutics BV

American Gene Technologies ...

Abivax SA

AdAlta Ltd

Advanced Genetic Systems Inc

Aelix Therapeutics SL

Akshaya Bio Inc

Altor BioScience Corp

Altravax Inc

Amarna Therapeutics BV

American Gene Technologies International Inc

Amunix Operating Inc

Antigen Express Inc

Aphios Corp

Apotex Inc

Argos Therapeutics Inc

Atreca Inc

Auritec Pharmaceuticals Inc

B Cell Design SAS

Biological Mimetics Inc

Bionor Holding AS

Biotron Ltd

Bolder Biotechnology Inc

Bristol-Myers Squibb Co

Bukwang Pharm Co Ltd

Cadila Healthcare Ltd

Calimmune Inc

Celgene Corp

Celldex Therapeutics Inc

Chipscreen Biosciences Ltd

Cocrystal Pharma Inc

CompleGen Inc

Consegna Pharma Inc

ContraVir Pharmaceuticals Inc

Curevac AG

Cytodyn Inc

CytRx Corp

Enzo Biochem Inc

Excision BioTherapeutics Inc

FIT Biotech Oy

Fountain Biopharma Inc

Frontier Biotechnologies Inc

GeneCure LLC

Genetic Immunity Inc

GeoVax Labs Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Globeimmune Inc

GW Pharmaceuticals Plc

Heat Biologics Inc

Hoverink Biotechnologies Inc

iCo Therapeutics Inc

ID Pharma Co Ltd

IGXBio Inc

Immune Response BioPharma Inc

Immunocore Ltd

Immunotope Inc

Immusoft Corp

ImQuest Life Sciences Inc

InnaVirVax SA

Innovare R & D SA De CV

Innovative Targeting Solutions Inc

Inovio Pharmaceuticals Inc

Japan Tobacco Inc

Johnson & Johnson

Kainos Medicine Inc

Karyopharm Therapeutics Inc

Kymab Ltd

Longevity Biotech Inc

MacroGenics Inc

Medivir AB

Merck & Co Inc

Moderna Therapeutics Inc

Mologen AG

Mutabilis SA

Mycenax Biotech Inc

Mymetics Corp

NanoViricides Inc

Navigen Inc

NeED Pharma srl

New World Laboratories Inc

Novartis AG

Omeros Corp

Oncolys BioPharma Inc

Oncovir Inc

Orbis Biosciences Inc

Osel Inc

OyaGen Inc

PaxVax Inc

Phoenix Biotechnology Inc

PlantForm Corp

Profectus BioSciences Inc

ReceptoPharm Inc

Recombio SL

Relmada Therapeutics Inc

Resverlogix Corp

Rodos BioTarget GmbH

Samjin Pharm Co Ltd

Sangamo Therapeutics Inc

Sanofi

Sanofi Pasteur SA

Shanghai Pharmaceutical Co Ltd

Shionogi & Co Ltd

Spider Biotech

Spring Bank Pharmaceuticals Inc

ST Pharm Co., Ltd.

Starpharma Holdings Ltd

Susavion Biosciences Inc

Taiga Biotechnologies Inc

TaiMed Biologics Inc

Takara Bio Inc

Takeda Pharmaceutical Co Ltd

TechnoVax Inc

TeneoBio Inc

TheraJect Inc

Theratechnologies Inc

Theravectys SA

Transgene Biotek Ltd

TVAX Biomedical Inc

United Biomedical Inc

Vaccibody AS

Vault Pharma Inc

VG Life Sciences Inc

Vichem Chemie Research Ltd

ViiV Healthcare UK Ltd

Vincogen Corp

Viriom Inc

ViroStatics srl

XL-protein GmbH

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Overview 9

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Development ...

Table of Contents

Table of Contents 2

Introduction 8

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Overview 9

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Development 10

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment 52

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development 67

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Drug Profiles 126

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects 887

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products 946

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones 953

Appendix 963

List of Tables

List of Tables

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2018

Number of Products under Development by Companies, H1 ...

List of Tables

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Products under Development by Companies, H1 2018 (Contd..15), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..4), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..5), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..6), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..7), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Abivax SA, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AdAlta Ltd, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Advanced Genetic Systems Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Aelix Therapeutics SL, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Akshaya Bio Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altor BioScience Corp, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altravax Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amarna Therapeutics BV, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by American Gene Technologies International Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amunix Operating Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Antigen Express Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Aphios Corp, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Apotex Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Argos Therapeutics Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Atreca Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Auritec Pharmaceuticals Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by B Cell Design SAS, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biological Mimetics Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bionor Holding AS, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biotron Ltd, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bolder Biotechnology Inc, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bristol-Myers Squibb Co, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bukwang Pharm Co Ltd, H1 2018

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Cadila Healthcare Ltd, H1 2018

List of Figures

List of Figures

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2018

Number of Products under Development by Companies, H1 ...

List of Figures

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports